Novo Nordisk's blockbuster weight loss drug semaglutide failed to slow Alzheimer's progression in trials. The studies had ...
Editas Medicine reported promising initial results from the EDIT-301 trials for inherited blood disorders, leading to a rating upgrade to "outperform" by Raymond James. The company's financial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback